Inflammatory cytokine pathways and cartilage catabolism

Inflammatory cytokine pathways and cartilage catabolism refer to the pathological signaling network where pro-inflammatory mediators drive the degradation of the joint extracellular matrix. Key cytokines such as Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor alpha (TNF-α) bind to their respective receptors on chondrocytes, triggering intracellular cascades including the NF-κB and MAPK pathways (Kapoor et al., 2011). This signaling results in the transcriptional upregulation of catabolic enzymes, primarily matrix metalloproteinases (MMPs) like MMP-13 and aggrecanases like ADAMTS-4 and ADAMTS-5, which proteolytically cleave collagen type II and aggrecan (Goldring & Goldring, 2007). This shift in balance from anabolic repair to catabolic destruction is a hallmark of osteoarthritis and rheumatoid arthritis, leading to permanent structural damage and loss of joint function (Wojdasiewicz et al., 2014). Pharmacological strategies aimed at this process include the use of biological agents to neutralize cytokines or small molecules to inhibit downstream kinases and proteases (Malfait et al., 2013).

Other names

Cytokine-mediated cartilage degradationPro-inflammatory signaling in osteoarthritisChondrocyte catabolic pathwayCytokine-induced proteolysis

Neutralization of pro-inflammatory cytokines or inhibition of downstream catabolic enzymes to prevent the degradation of type II collagen and aggrecan.